BIOREGULATORY APPROACH TO COMBINATION THERAPY FOR PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper gives the results of an open-label longitudinal randomized study, which suggest that is expedient to incorporate the antihomotoxic agents Spascupreel and Mucosa compositum into combination therapy for patients with gastroesophageal reflux disease; the drugs regress the symptoms of the disease, increase the period of remission, and improve the results of endoscopic studies and the indicators of quality of life.

Full Text

Restricted Access

About the authors

N. Komleva

Saratov Research Institute for Agricultural Hygiene, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: NEKomleva@yandex.ru
MD; Professor Moscow

A. Maryanovsky

N.I. Pirogov Russian National Research Medical University

MD Moscow

A. Danilov

Saratov Research Institute for Agricultural Hygiene, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Associate Professor Candidate of Medical Sciences Moscow

I. Zaikina

Saratov Research Institute for Agricultural Hygiene, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Candidate of Medical Sciences Moscow

References

  1. Bashashati M., Hejazi R., Andrews C. et al. Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia? // Can. J. Gastroenterol. Hepatol. -2014; 28 (6): 335-41.
  2. Bruley des Varannes S., Cestari R., Usova L. et al. Classification of adults suffering from typical gastroesophageal reflux disease symptoms: contribution of latent class analysis in a European observational study // BMC Gastroenterol. -2014; 14: 112.
  3. El-Serag H., Sweet S., Winchester C. et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review // Gut. - 2014; 63 (6): 871-80.
  4. Mason J., Hungin A. Review article: gastro-oesophageal reflux disease -the health economic implications // Aliment. Pharmacol. Ther. - 2005; 22 (1): 20-31.
  5. Tack J., Becher A., Mulligan C. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life // Aliment. Pharmacol. Ther. - 2012; 35 (11): 1257-66.
  6. Nwokediuko S. Current trends in the management of gastroesophageal reflux disease: a review // ISRN Gastroenterol. - 2012; ID391631.
  7. Boeckxstaens G., El-Serag H., Smout A. et al. Symptomatic reflux disease: the present, the past and the future // Gut. - 2014; 63 (7): 1185-93.
  8. Subramanian C., Triadafilopoulos G. Refractory gastroesophageal reflux disease // Gastroenterol. Rep. - 2015; 3 (1): 41-53.
  9. Bueno L., Lafforgue G., Beaufrand C. et al. Colonic and anorectal disorders targeting the IBS pathophysiology in stressed rats using a multicomponent HE-400 // J. Gastroenterol. Hepatol. - 2013; 28 (suppl. 3): 347-8.
  10. Комлева Н.Е., Спирин В.Ф., Заикина И.В. Изучение эффективности антигомотоксической терапии ГЭРБ // Международный журнал прикладных и фундаментальных исследований. - 2015; 8-1: 52-4.
  11. Lundell L., Dent J., Bennett J. et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angelesclassification // Gut. - 1999; 45 (2): 172-80.
  12. Ware J. SF-36 Health Survey Update // Spine. - 2000; 25: 3130-9.
  13. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине / СПб: Нева, 2002; 320.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Russkiy Vrach Publishing House